Key Highlights

  • Shares are trading at $6.09 in pre-market activity, down 10.16% from Thursday's close of $6.78.
  • The pullback follows Thursday's 374.13% single-session surge after Aethlon announced a definitive Merger agreement with North Immunology.
  • The merger is paired with an oversubscribed $180 million private Placement expected to fund the combined company's operations into the second half of 2028.
  • The combined company will operate as North Immunology, trading under the new ticker NRTX, with pre-merger Aethlon stockholders expected to own approximately 4.75% of the combined entity.

Shares Cool Off After Thursday's Historic Merger Rally

Aethlon Medical (NASDAQ:AEMD) shares pulled back in pre-market trading Friday, cooling off after Thursday's 374.13% single-session surge on news of a definitive merger agreement with North Immunology, a privately held biotechnology company developing bispecific antibodies for immune and inflammatory diseases. Aethlon Medical is a San Diego-based clinical-stage medical device company that has been developing the Hemopurifier, an investigational extracorporeal device designed to remove harmful tumor-derived exosomes and enveloped viruses from the bloodstream.

Deal Terms Remain Unchanged as Shares Digest the Prior Move

The merger structure itself has not changed: it remains paired with an oversubscribed private placement expected to provide approximately $180 million in gross proceeds, funding the combined company's operations into the second half of 2028. Upon closing, the combined entity will operate as North Immunology, trading on the Nasdaq Capital Market under the new ticker symbol NRTX, with pre-merger Aethlon stockholders expected to own approximately 4.75% of the combined company.

Today's Pullback Looks Like Digestion, Not a Reversal of the Story

Today's decline appears consistent with profit-taking after Thursday's outsized single-day move rather than any new negative development, since no changes to the merger terms, financing, or clinical timeline for lead candidate NOR-101 have been disclosed. Aethlon stockholders will also retain contingent value rights tied to any future monetization of the company's legacy Hemopurifier business, a feature of the deal that remains intact.